InvestSMART

CurveBeam AI Limited (ASX:CVB)

ALERT: Price-sensitive ASX Announcement for CVB
Current share price for CVB : $0.027 -0.048 (-64%)+
Announcement
Release
7 Jan 2026 9:53AM
Price at Release
$0.075
Full Release
download
Summary
CurveBeam AI Limited, an Australian company specializing in point-of-care medical imaging, has received China ODI approval for a strategic investment from Shandong WeiYing Intelligent Medical Technology Co., Ltd. This investment is part of a broader 10-year commercialization agreement in China and associated regions, involving a total of up to A$10 million, with an initial tranche of A$4 million. The funds will support CurveBeam AI's weight-bearing CT and AI technologies expansion in Greater China, backed by WEGO Orthopaedics, a leading Chinese orthopaedic device company.
Key Points
  • CurveBeam AI receives China ODI approval for investment.
  • Investment from Shandong WeiYing part of a larger A$10 million deal.
  • Initial A$4 million tranche to be received in January 2026.
  • 10-year agreement covers commercialization in Greater China.
  • Supported by WEGO Orthopaedics, a major Chinese orthopaedic supplier.
  • Funds to enhance regulatory, manufacturing, and commercial activities.
  • Shares issued at A$0.405 per share, a premium over market price.
  • Investment strengthens financial position and global growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.